Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296
Resource Type
Erratum
Authors
Babu, Sunil ; Broeders, Nilufer ; Lietar, Nicole ; Brown, Fiona ; Campbell, Philip ; Campistol, Josep M. ; Blasco, Miquel ; Chowdhury, Paramit ; Kasimatis, Theo ; Cirami, Lino ; Caroti, Leonardo ; Antognoli, Guilia ; Delmas, Yahsou ; Dobronravov, Vladimir ; Gaeckler, Anja ; Garrouste, Cyril ; Greenwood, Gregory ; Griffin, Siân ; Huang, Chiu-Ching ; Chen, I-Ru ; Huang, Susan ; Kim, Jin Seok ; La Manna, Gaetano ; Comai, Giorgia ; Cappuccilli, Maria ; Le Quintrec, Moglie ; Jeantet, Guillaume ; Fumie, Iino ; Luque, Yosu ; Menne, Jan ; Morelle, Johan ; Goffin, Eric ; Muhlfeld, Anja ; Nagaraj, Shashi ; Arepally, Gowthami ; Oh, Doyeun ; Okumi, Masayoshi ; Terente, Manuel Praga ; Gutierréz, Elena ; Rodriguez, Paola ; Provot, Francois ; Schönermarck, Ulf ; Fischereder, Michael ; Terrada, Natalia Ramos ; Seitz-Polski, Barbara ; Favre, Guillaume ; Boyer-Suavet, Sonia ; Vinogradova, Maria ; Kirsanova, Tatiana ; Wong, Edwin K.S. ; Rondeau, Eric ; Scully, Marie ; Ariceta, Gema ; Barbour, Tom ; Cataland, Spero ; Heyne, Nils ; Miyakawa, Yoshitaka ; Ortiz, Stephan ; Swenson, Eugene ; Vallee, Marc ; Yoon, Sung-Soo ; Kavanagh, David ; Haller, Hermann
Source
In Kidney International May 2021 99(5):1244-1244
Subject
Language
ISSN
0085-2538